Cargando…

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency

Detalles Bibliográficos
Autores principales:	Martin, Adriana, Lavoie, Louis, Goetghebeur, Mireille, Schellenberg, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487819/ http://dx.doi.org/10.1186/1710-1492-8-S1-A20

Ejemplares similares

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, A, et al.
Publicado: (2013)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
por: Walter, Graham, et al.
Publicado: (2020)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy
por: Pourshahnazari, Persia, et al.
Publicado: (2014)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Basic and clinical immunology – 3030. Subcutaneous immunoglobulin therapy: An option for patients who have experienced thrombotic complications with intravenous therapy
por: Moss, Leslie Anne, et al.
Publicado: (2013)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
por: Smith, Susan E., et al.
Publicado: (2023)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
por: Chapdelaine, H, et al.
Publicado: (2012)

Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia
por: Levasseur, Marie-Claude, et al.
Publicado: (2012)

In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins
por: Leidenmühler, Peter, et al.
Publicado: (2023)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
por: Jonaitis, Laimas, et al.
Publicado: (2021)

Unusual presentation of a patient with complement deficiency and immunoglobulin deficiency
por: Manga, Vaishaali, et al.
Publicado: (2014)

2562. Retrospective Analysis of Cefepime Intravenous Push versus Extended Infusion for the Treatment of Neutropenic Fever
por: Rust, Thomas J, et al.
Publicado: (2023)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

541 Intravenous Immunoglobulin in Leukocyte Adhesion Deficiency
por: Oropeza, Said Arablin, et al.
Publicado: (2012)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Pushing the agenda for intravenous push administration in outpatient parenteral antimicrobial therapy
por: Johnson, Tanner M., et al.
Publicado: (2023)

Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study
por: Palabrica, Frances Rose R., et al.
Publicado: (2013)

Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions
por: Georgiadou, Sarah, et al.
Publicado: (2019)

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
por: Kato, Hidefumi, et al.
Publicado: (2021)

Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles
por: Abbott, Jordan K., et al.
Publicado: (2022)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
por: Visentin, Andrea, et al.
Publicado: (2022)

Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
por: Falanga, Marina, et al.
Publicado: (2018)

Safety of rapid intravenous paracetamol infusion in paediatric patients
por: Eliasen, Astrid, et al.
Publicado: (2021)

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
por: Cowan, Juthaporn, et al.
Publicado: (2020)

Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion
por: Mizrahi, Meir, et al.
Publicado: (2009)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study
por: Ritchie, Bruce, et al.
Publicado: (2022)

Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient
por: Pegler, José Roberto Mendes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uta7au44f1qaut847mjfbk26l5